synthesized and tested in vitro for pi, d and x receptor affinities. They were found to have potent opioid receptor binding activity. The (25,35)-butanediol bridge configuration yield ed selectivity and high potency for pi and x receptors, while the (2/?,37?)-butanediol bridge configuration yielded high potency and selectivity for < 3 receptors. It thus appears that changes in the length and configuration of the polyhydroxyl bridge in dimeric enkephalin analogues can produce a shift in receptor selectivity profiles and therefore suggest the possibility of developing more selective drugs.
Introduction
O ne of the promising possibility of developing new opioid analogues is the synthesis of compounds containing two pharmacophores in one molecule [1] [2] [3] [4] [5] [6] [7] . Analogues called dimeric [4, 5] , double [3] or bivalent [8] enkephalins which contain bridges of various type and length between two active peptide fragm ents belong to this class of compounds. The nature of a bridge can alter, both, biological activi ty and selectivity toward opioid receptors of an analogue due to increase of enzymatic resistance and possibility of simultaneous interaction with two re ceptor sites.
Shimohigashi et al. [4, 5] have synthesized dim er ic analogues of enkephalins in which two peptide fragm ents were connected at the C-terminus by a,ö>-diaminoalkanes of variable length. The analo gues exhibited generally high selectivity for < 5 recep tors, and the authors suggested that such dimers could serve as bivalent ligands binding simulta neously to two distinct but closely clustered < 5 recep tors. Lipkowski et al. [3, 9] have shown that even a shorter bivalent enkephalin analogue with a dihydrazide bond possessed relatively high activity and also <5 receptor selectivity.
Recently, in an effort to reduce the conforma tional flexibility and to obtain more selective active compounds, a num ber of laboratories [10] [11] [12] have developed glycosylated enkephalin analogues which contained a sugar moiety linked to a peptide pharm ocophore through various chemical bonds and showed high biological activities.
The above observations encouraged us [13] to synthesize two dimeric enkephalin analogues with hydrophilic bridges derived from 1,4-diamino-1,4-dideoxy-and l,6-diamino-l,6-dideoxyalditols bearing two and four vicinal hydroxyl groups, respectively. These closely related analogues ex pressed com parable affinity for d receptors but displayed significant differences in binding affinity for pi and x receptors. The shorter spacer resulted in analogue with selectivity and high affinity for H and x receptors.
In the present study we report the syntheses of three new analogues within this series. The short spacers having one or two hydroxyl groups of various configuration have been used for bridging two peptide pharmacophores. The effect of length as well as configuration of a spacer on selectivity of a bivalent opioid ligand was of inter est in this study.
Experimental

Chemical synthesis
Thin layer chromatography (TLC) was per formed on silica gel (Kieselgel G The 13C NM R spectra were obtained with a Jeol FX 90 Q spectrometer. The liquid m atrix secondary ions mass spectrometry (LSIMS) was perform ed on an AMD-604 Intectra Gm bH spectrometer. A na lytical HPLC analyses were perform ed on a Spectra-Physics SP 8800 liquid chromatograph, utilizing an analytical Supelco LC-18-T (25 cm, 5 /im, with a 2 cm guard) reversed phase column. The solvent system was buffer A (0.01 M K H 2P 0 4, pH 3.0) and buffer B (50% buffer A/50% acetonitrile, v/v). The linear gradient was 40-100% B in 20 min, the flow rate 2.0 ml/min, and monitoring was perform ed at 210 nm. Semipreparative HPLC was perform ed on a Supelco LC-18-DB reverse phase column with linear gradients of buffer A (0.03 M ammonium acetate, pH 5.0) and buffer B (33% buffer A/67% acetonitrile, v/v) and monitoring at 230 or 260 nm. (3) were prepared according to known procedures [14] [15] [16] from l,3-dichloro-2-propanol [17] , l^-dichloro-l^-dideoxy-m eso-erythritol [18] and D -tartaric acid, respectively. Their 13C NMR chemical shifts are given in Table I. 2 (6) were prepared from appro Table 1 .13C NMR data assignments for characteristic carbon atoms in intermediates: 1 -6 ,7 a, 8 a and 9 a (<5 in ppm). a Signals for carbonyl carbon atoms were observed but not assigned; b d ' signals overlapped;e signal not observed because of overlapping with strong solvent lines; c'f-s-h assignments may be reversed.
priate diamines (1 -3 ) and Boc-L-phenylalanine by the DCC-catalyzed coupling reaction in DM F as previously described [13] and subsequent depro tection with 4 N HCI in ethyl acetate at room tem perature for 1 h. 13C NMR chemical shifts for com pounds 4 -6 are shown in Table I .
The tripeptide B o c -T y r -D -
A la -G ly was pre pared according to Lipkowski et al. [3] .
l,3-Di-(tyrosyl-D-alanyl-glycyl-phenylalanylamido)-2-propanol (7b)
. A solution of B o c -T y r -D -A la -G ly (409 mg, 1 mmol) in DMF (2 ml) was placed on a magnetic stirrer, cooled to -2 0 °C and neutralized with NMM (0.11 ml, 1 mmol); then iso butyl chloroformate (0.136 ml, 1 mmol) was added. The tem perature of the reaction mixture was m ain tained at -2 0 °C to -15 °C for 15 min, and then a solution of compound 4 (0.5 mmol) with NMM (0.11 ml, 1 mmol) in DMF (5 ml) was added. The stirring was continued for 1 h at room tem perature. A t that time, the mixture was concentrated (1 mm Hg) and taken up with four 50 ml portions of slight ly warmed ethyl acetate. The organic extracts were washed with 10% citric acid, 10% NaCl, saturated N aH C O s solution, water and dried over anhydrous Na2S 0 4. The solution was concentrated and the res idue purified on a silica gel column using a gradient solvent system from 5 to 33% (v/v) m ethanol in chloroform. Appropriate fractions were pooled and concentrated to give compound 7 a (211 mg, 36.2%). The 13C NMR spectrum (Table I) con firmed the expected structure. The Boc-protecting groups in compound 7 a (169 mg, 0.14 mmol) were removed by treatm ent with 4 N HCI in ethyl ace tate at room tem perature for 1 h. After concentra tion, the residue was purified on a Sephadex G-25 column using «-butanol -acetic acid -water (4 :1 :5 , upper phase) as solvent. Fractions containing com pound 7 b were pooled and lyophilized (85 mg, 60.7%).
Analytical HPLC of 7 b revealed single peak For the receptor binding assay purpose, an ana lytical sample of the compound 7 b was obtained by additional semipreparative HPLC purification.
l,4-Di-(tyrosyl-D-alanyl-glycyl-phenylalanylamido)-(2R,3S)-butanediol (8b). The coupling reaction of B o c -T y r-D -
A la -G ly (1 mmol) with compound 5 (0.5 mmol) was carried out in the same way as described above for compound 7 a. The obtained DMF solution was poured into a chilled mixture of 10% citric acid (30 ml) and 10% NaCl solution (30 ml) with stirring. The precipitation was filtered and washed successive ly with water, saturated N a H C 0 3 solution and water. Recrystallization from a relatively big volume of ethyl acetate (200 ml) gave 276 mg (46.1%) of 8 a. 13C NM R chemical shifts for the compound are shown in Table I 
1,4-Di-(tyrosyl-D-alanyl-glycyl-phenylalanylamido)-(2 R,3 R)-butanediol (9b)
. Com pound 9 a was prepared from the Boc-tripeptide (1 mmol) and com pound 6 (0.5 mmol) in the same m anner as de scribed above for compound 8 a. Yield: 276 mg (46.1%). 13C NM R chemical shifts for this com pound are shown in Table I . Compound 9 a (24 mg, 0.02 mmol) was deprotected with 4 N HCI in ethyl acetate, and the resulted product was purified by semipreparative HPLC. A fter lyophilization, com pound 9 b (9 mg, 45%) was obtained in pure form.
Analytical HPLC of 9 b gave single peak 
Receptor binding assays
Brains were dissected from decapitated male Hartley guinea pigs. Brain membranes prepara tion and receptor binding assays were performed as described previously [19, 20] . The final concen tration of labelled ligands used were: 0. [9] ;c reference [13] .
Results and Discussion
The syntheses of the new three dimeric enke phalin analogues 7 b, 8 b and 9 b were carried out according to our previously reported strategy [13] . The synthetic route is outlined in Fig. 1 . The two diamine synthons 1 and 2 were prepared by means of Gabriel reaction [14] from glycerol and mesoerythritol via their dichlorodideoxy derivatives [17, 18] . Compound 3 was synthesized from D-tartaric acid in few steps as described by Kiely et al. [16] for the L enantiomer. Analytical data for the diamines in appropriate forms of dihydrohalides were in good accord with the expected structures. Coupling reactions of the above diamines with Nprotected phenylalanine were carried out in DM F using the D CC-HOBt method. The coupling prod ucts exhibited very low solubility in w ater and any inert organic solvent. Their NM R spectra were taken after deprotection of the amino groups (Table I , compounds: 4, 5 and 6). Next, the mixed anhydride m ethod was used for the connection of the N-Boc protected tripeptide with the phenyl alanine residues. A ttem pts to use the D CC-HOBt coupling method on this stage have also been made, but they indicated poorer perform ance in relation to the mixed anhydride synthesis due to, both, yield and purity of the crude products. Target dimeric analogues were obtained after deprotection of the Boc group, chromatographic purification and lyophilization. Products 7 b, 8 b and 9 b were obtained as fine, white powdery compounds with the correct amino acid analyses and LSIMS spectra. Analytical HPLC gave single peaks for these substances.
The dimeric analogues were tested for receptor binding to /u, d and x receptors in guinea pig brain homogenates by the methodology identical with that used previously for characterization of other bivalent ligands [9, 13] . The K; values are presented in Table II an even more spectacular increase of 40 times for x receptors, while the affinity for d receptors was not significantly affected. Thus, both, the length and configuration of the spacer are im portant factors in determining receptor potency and selectivity within this series. It thus appears that the use of hydrophilic spacers creates new possibilities in the modulation of activity and selectivity of opioid peptide bivalent ligands.
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